Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference Chemomab presents new data supporting clinical potential of CM-101 as novel treatment for PSC at EASL 2024 and Gordon Research Conference

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024 Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis Chemomab has gained a new EU patent for CM-101 covering its use in liver diseases including PSC, adding to the robust patent estate in major territories.

Primary Sclerosing Cholangitis Pipeline: Therapeutic Assessment, Emerging Drugs and Growth Prospects Analysis | DelveInsight New York, USA, April 27, 2022 (GLOBE NEWSWIRE) -- Primary Sclerosing Cholangitis Pipeline: Therapeutic Assessment, Emerging Drugs and Growth Prospects Analysis | DelveInsight Primary Sclerosing...